SC
ADPT icon

Stephens Consulting’s Adaptive Biotechnologies ADPT Stock Holding History

Stephens Consulting’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-45
Closed -$335 – 1202
2025
Q1 		$335 Buy
+45
New +$346 ﹤0.01% 1404

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Stephens Consulting's ADPT Position: Q2 2025 in Review

Stephens Consulting sold out of Adaptive Biotechnologies (ADPT) in Q2 2025, closing a stake of 45 shares — an estimated $335 sold.

Stephens Consulting first reported a position in ADPT in Q1 2025 and held it in 1 quarter. The position peaked at $335 in Q1 2025. 242 funds tracked by Wall St. Rank hold ADPT as of Q2 2025.

  • Stephens Consulting reported no remaining Adaptive Biotechnologies position as of Q2 2025 after selling out during the quarter.
  • Stephens Consulting sold 45 Adaptive Biotechnologies shares in Q2 2025, an estimated $335.
  • Stephens Consulting first reported a position in Adaptive Biotechnologies in Q1 2025 and held it in 1 quarter.
  • Stephens Consulting's Adaptive Biotechnologies position peaked at $335 in Q1 2025.
  • 242 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2025.

Based on Stephens Consulting's 13F filing for Q2 2025, filed 25 Jul 2025.